TCS7010
Based on 2 publication(s) in Google Scholar
TCS7010 is a potent and highly selective Aurora A inhibitor with with an IC50 of 3.4 nM.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 1158838-45-9
- Formula: C31H31ClFN7O2
- Molecular Weight:588.08
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Blood Cancer Compound Library
HY-L079
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) TCS7010
MoreAll Aurora Kinase Isoforms
More
Biological Activity
|
Aurora A 3.4 nM (IC50) |
Aurora B 3.4 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
>50 μM
Compound: 10
|
Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
|
[PMID: 19402633] |
| HCT-116 | IC50 |
0.19 μM
Compound: 10
|
Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay
Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay
|
[PMID: 19402633] |
| HCT-116 | IC50 |
0.39 μM
Compound: 10
|
Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay
Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay
|
[PMID: 19402633] |
| HCT-116 | IC50 |
190 nM
Compound: 73
|
Growth inhibition of human HCT116 cells by XTT assay
Growth inhibition of human HCT116 cells by XTT assay
|
[PMID: 28918096] |
| HCT-116 | IC50 |
2.5 μM
Compound: 10
|
Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay
Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay
|
[PMID: 19402633] |
| HeLa | IC50 |
416 nM
Compound: 73
|
Growth inhibition of human HeLa cells by XTT assay
Growth inhibition of human HeLa cells by XTT assay
|
[PMID: 28918096] |
| HT-29 | IC50 |
>27 μM
Compound: 10
|
Inhibition of Aurora B in human HT29 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
Inhibition of Aurora B in human HT29 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
|
[PMID: 19402633] |
| HT-29 | IC50 |
2.9 μM
Compound: 10
|
Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay
Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay
|
[PMID: 19402633] |
| HT-29 | IC50 |
2.9 μM
Compound: 73
|
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
|
[PMID: 28918096] |
| HT-29 | IC50 |
5.6 μM
Compound: 73
|
Growth inhibition of human HT-29 cells by XTT assay
Growth inhibition of human HT-29 cells by XTT assay
|
[PMID: 28918096] |
| KCL-22 | IC50 |
5 μM
Compound: 73
|
Induction of apoptosis in human KCL22 cells by Annexin V staining based assay
Induction of apoptosis in human KCL22 cells by Annexin V staining based assay
|
[PMID: 28918096] |
| NCI-H82 | IC50 |
1 nM
Compound: Aurora A Inhibitor 1
|
Growth inhibition of human NCI-H82 cells assessed as reduction in cell viability after 72 hrs by PrestoBlue Cell Viability assay
Growth inhibition of human NCI-H82 cells assessed as reduction in cell viability after 72 hrs by PrestoBlue Cell Viability assay
|
[PMID: 34009981] |
| SK-N-BE(2) | IC50 |
1 nM
Compound: Aurora A Inhibitor 1
|
Growth inhibition of human SKNBE2 cells assessed as reduction in cell viability after 72 hrs by PrestoBlue Cell Viability assay
Growth inhibition of human SKNBE2 cells assessed as reduction in cell viability after 72 hrs by PrestoBlue Cell Viability assay
|
[PMID: 34009981] |
TCS7010 is exceptionally selective Aurora A inhibitors. TCS7010 is an useful tool compounds for investigating the cellular role of Aurora A kinases without the complication of also inhibiting Aurora B[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1158838-45-9
-
Appearance Solid
-
Molecular Weight 588.08
-
Formula C31H31ClFN7O2
-
Color White to light yellow
-
SMILES
O=C(C1=CC=C(C=C1)NC2=C(F)C=NC(NC3=CC=C(C=C3)CC(N4CCN(CC4)CC)=O)=N2)NC5=CC=CC=C5Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
Chromatin-associated α-satellite RNA maintains chromosome stability by reestablishing SAF-A in the mitotic cell cycle. [Abstract]2025 Apr 10;53(7):gkaf294. PMID: 40219970 -
J Biomol Screen
Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay. [Abstract]2013 Oct;18(9):1062-71. PMID: 23788527
Solvent & Solubility
DMSO : 50 mg/mL (85.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Aliagas-Martin I, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang OW, Hunsaker T, Kleinheinz T, Krueger E, Liang J, Moffat J, Phillips G, Pulk R, Rawson TE, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhu BY, Cochran AG.A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.J Med Chem. 2009 May 28;52(10):3300-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7004 mL | 8.5022 mL | 17.0045 mL | 42.5112 mL |
| 5 mM | 0.3401 mL | 1.7004 mL | 3.4009 mL | 8.5022 mL | |
| 10 mM | 0.1700 mL | 0.8502 mL | 1.7004 mL | 4.2511 mL | |
| 15 mM | 0.1134 mL | 0.5668 mL | 1.1336 mL | 2.8341 mL | |
| 20 mM | 0.0850 mL | 0.4251 mL | 0.8502 mL | 2.1256 mL | |
| 25 mM | 0.0680 mL | 0.3401 mL | 0.6802 mL | 1.7004 mL | |
| 30 mM | 0.0567 mL | 0.2834 mL | 0.5668 mL | 1.4170 mL | |
| 40 mM | 0.0425 mL | 0.2126 mL | 0.4251 mL | 1.0628 mL | |
| 50 mM | 0.0340 mL | 0.1700 mL | 0.3401 mL | 0.8502 mL | |
| 60 mM | 0.0283 mL | 0.1417 mL | 0.2834 mL | 0.7085 mL | |
| 80 mM | 0.0213 mL | 0.1063 mL | 0.2126 mL | 0.5314 mL |
TCS7010 Related Classifications
HY-70061 Related Classifications
Powered by Bioz